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01/01/2009 and 31/01/2013 were identified in The Health Improvement Network 
(THIN) database. Patients were excluded if they had history of; chronic kidney dis-
ease stage 4/5, cancer, neuropathic pain, sciatica/radiculopathy, diabetes, back pain 
or a prior prescription for a study drug. Patients were classified as responders if they 
were either “cured” (discontinued treatment) or stable (remained on treatment), 
or a non-responder if they were referred to a pain clinic or switched to a CYP2D6-
independent analgesic. Multivariate logistic regression was used to identify the pre-
dictors of response and estimate the influence of CYP2D6-inhibitors. Results: The 
cohort consisted of 43,632 patients: 90.8% were responders, and CYP2D6-inhibiting 
drugs were prescribed to 33.8% of the cohort. Almost three times as many patients 
failed to respond in those prescribed a CYP2D6-inhibitor (16% vs. 6%). Controlling 
for medication, demographics and co-morbidities the logistic regression indicated 
the odds of responding for those with a CYP2D6-inhibiting co-prescription were 
39% lower than those without a co-prescription for a CYP2D6 inhibiting drug (OR= 
0.61, 95% CI 0.57 to 0.66). ConClusions: Chronic non-malignant pain patients 
with a co-prescription for a CYP2D6-inhibiting medication were significantly less 
likely to respond to analgesia treatment and therefore received suboptimal pain 
management.
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objeCtives: Transfusional iron overload is common among patients with myelo-
dysplastic syndromes (MDS) receiving red blood cell (RBC) transfusions. Emerging 
evidence indicates that iron chelation therapy (ICT) could improve health outcomes 
in MDS patients with low/intermediate-1 IPSS risk. This study aimed to investigate 
clinical evolution and transfusion dependency of MDS patients under ICT with 
deferasirox, in clinical practice. Methods: This was a retrospective analysis of a 
hospital registry of MDS patients followed-up by imunohemotherapy. Longitudinal 
data records were aggregated in 3 months periods. Exploratory analysis was per-
formed to characterize patients. Generalized Estimation Equation models were 
used to estimate the effect of time on average ferritin levels and RBC transfusions, 
controlled by patient’s initial conditions and deferasirox dose. Generalized Linear 
Mixed-effects Models were estimated to assess individualized evolution patterns. 
In modelling only patients chelated for ≥ 6 months were considered. Results: A 
total of 877 records of 17 MDS patients (53% male), classified as low risk at diagnosis, 
were included in the analysis. Median ages at diagnosis, beginning of RBC transfu-
sions and beginning of ICT were 71, 74 and 77, respectively. Patients had received 
an average of 51.6±26.2 RBC units before ICT. Average values of clinical param-
eters were calculated for each patient. Sample medians were: ferritin 3674.3ng/mL, 
hemoglobin 8.2g/dL, alkaline phosphatase 91.3UI/L, gamma-glutamyl transferase 
0.4UI/L, aspartate aminotransferase 27.0UI/L, alanine aminotransferase 42.9UI/L and 
blood creatinine 0.9mg/dL. From the 8 patients chelated ≥ 6 months: 6 presented 
a decrease on ferritin levels and 4 presented a decrease in RBC transfusions (one 
reaching transfusional independence), over time. Marginal models demonstrated 
that average ferritin levels and number of RBC decrease with time (β = -141.9 p= 0.008; 
β = -0.043 p= 0.001, respectively). ConClusions: Analysis of real-world data from 
a Portuguese registry of transfusion-dependent MDS patients chelated with def-
erasiforx, for ≥ 6month, indicated that both ferritin levels and RBC transfusions 
tend to decrease with time.
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objeCtives: To study the clinical presentations, treatment pattern and outcome of 
patients diagnosed with Guillain-Barre Syndrome (GBS). Methods: A retrospective 
observational study, carried out in a tertiary care teaching hospital. Data of patients 
diagnosed with GBS and admitted to ICUs, medical wards and neurological wards 
from 2008 to 2013, was collected from medical records department (MRD) registry 
using ICD-10 code G61.0 Results: During the study period total 130 patients were 
diagnosed with GBS. The mean age of the study population was 35.3±20.7 years 
(mean±SD) and 55.4% (n= 72) patients were male. Hospital admissions due to GBS 
showed a marked escalation yearly from 2008 to 2013. 48.4% (n= 63) of patients 
reported flu like syndrome along with loose stools one week prior to GBS onset. The 
main clinical manifestations of GBS, bilateral ascending weakness and areflexia 
was seen in 69.2% of patients. Respiratory paralysis is the major cause of mortality 
in GBS patients and was present in 17.7% (n= 23) of the patients. Among the study 
population 49.2% (n= 64) of patients received intravenous Ig (IVIg) therapy and 11.5% 
(n= 15) of patients underwent plasmapheresis. Other supportive therapies included 
were physiotherapy/occupational therapy (13.8%) and corticosteroid therapy (10.8%). 
Due to high economic burden 14.6% (n= 19) of patients denied all treatments. Among 
the patients who received IVIg therapy, 4.7% showed complete recovery and 82.8% 
showed significant improvement whereas patients who received plasmapheresis, 
85.7% showed significant improvement. The mortality rate in patients who received 
IVIg was 1.6% whereas in plasmapheresis was 7.1%. ConClusions: Both IVIg and 
plasmapheresis treatments showed significant improvement within 3 weeks. In 
our study setting, IVIg was the preferred treatment option due to low side effect 
profile and ease of administration however cost of treatment is higher compared 
to plasmapheresis. Plasmapheresis was associated with complications such as BP, 
HR fluctuations.
the 12-month baseline period, 26% of patients experienced 1 PEx, 15% had 2, and 
20% had ≥ 3. Corresponding proportions over a mean of 27 months of follow-up 
were 16%, 12%, and 52%. The mean PEx rate rose from 1.3 to 1.6/patient-year 
from baseline to follow-up. In the follow-up period, proportions of patients with 
at least 1 PEx and rates of PEx were higher among adults (84%; 1.7/patient-year) 
versus adolescents (70%; 1.5/patient-year) and for patients in the severe ppFEV1 
group (86%; 2.0/patient-year) compared with the mild group (70%; 1.1/patient-
year). Among patients with PEx, 61% required inpatient hospitalization (mean ± 
SD length of stay, 13.3 ± 7.4 days) and 73% required either hospitalization or IV 
antibiotics. ConClusions: The majority of patients with CF homozygous for the 
F508del CFTR gene mutation experience at least one PEx annually and many PEx 
are associated with lengthy hospitalizations. The rates of PEx increase over time 
and are highest for adults and for those in the most severe lung function group, 
consistent with a progressive disease.
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objeCtives: MICA antibody identification is a test performed on transplant 
patients to check for the presence of donor-specific MICA for the purpose of pre-
dicting the incidence of organ rejection among transplant patients. The purpose 
of this assessment was to evaluate the effectiveness. Methods: The literature 
search was performed using 8domestic research databases and 3core databases. A 
total of 9papers that remained. Each of the stages from literature search to applica-
tion of selection criteria and data extraction was independently by 2researcher. 
The SIGN was used for the quality assessment. Results: There were 5studies 
reporting on the medical results of kidney transplant patients. 2of the studies 
reported no significant differences in the graft survival rate and incidence of organ 
rejection(p= .67). There were 3studies reporting of heart transplant patients. There 
was one study reporting of lung transplant patients. The incidence of organ rejec-
tion was reported to be 42.0%(p= ns). ConClusions: MICA Identification lacked 
clinical effectiveness for the following reasons: i)there were no significant differ-
ences in the graft survival rate and incidence of organ rejection; ii)it is difficult to 
determine whether the different results for the graft survival rate and incidence 
of organ rejection reported.
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objeCtives: The efficacy and safety of capsaicin 8% patch (Qutenza) for treat-
ing painful diabetic peripheral neuropathy (PDPN) has recently been studied but 
direct comparison with other treatments is lacking. The objective was to obtain 
estimates of the relative efficacy and safety of oral treatments for PDPN and cap-
saicin 8% patch. Methods: A systematic literature review (SLR) and network 
meta-analysis (NMA) were conducted. The SLR collated data from all published 
randomized controlled trials (RCTs) comparing either pregabalin, duloxetine, 
amitryptiline or gabapentin. Efficacy data for capsaicin 8% patch was obtained 
from 12-week placebo-controlled RCT (STEP) and a 12-month open-label ran-
domized study versus standard of care (PACE). Electronic databases (Embase, 
Medline, CRD-Dare and Cochrane) were searched up to February 2014. Search 
results were screened, eligible studies were assessed for risk of bias and data 
were extracted. Efficacy outcomes selected for Bayesian NMA (WinBUGS v.1.4) 
included responder status (≥ 30%/ ≥ 50% reduction in pain) and absolute change 
in pain score from baseline. Safety endpoints included nausea, diarrhoea, som-
nolence and dizziness. Results: Out of the 400 unique records identified, 24 
were eligible for inclusion in the review. Eight studies were included in the NMA 
for ≥ 30% pain reduction, 10 for ≥ 50% pain reduction, and 11 reporting pain score 
change. No significant differences were observed between treatments regard-
ing either responder rate based on ≥ 30%/ ≥ 50% pain reduction or pain score 
change from baseline. Scenario analyses considering different dosing regimens 
of pregabalin and duloxetine, different definitions of clinical endpoints and inclu-
sion of PACE trial data did not significantly change the results. The capsaicin 8% 
patch exhibited none of the investigated safety events, whereas all orals reported 
dose-dependent side-effects. ConClusions: This NMA found that capsaicin 
8% patch, pregabalin, duloxetine, and gabapentin do not have different efficacy 
profiles for PDPN; however, capsaicin 8% patch exhibits fewer systemic adverse 
events.
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objeCtives: To determine the rates of co-prescription of CYP2D6-inhibiting medi-
cations with pain medication and the impact on response rates to pain medications, 
in the UK primary care setting. Methods: Codeine and tramadol are prodrugs 
requiring activation by the CYP2D6 enzyme. These drugs may have limited effective-
ness when co-prescribed with other medications known to inhibit the CYP2D6 path-
way. This contrasts with CYP2D6-independent analgesia, e.g. buprenorphine, which 
do not require CYP2D6 activation. We identified the co-prescription of three study 
pain medications; buprenorphine, codeine and tramadol with CYP2D6-inhibiting 
drugs including amitriptyline and fluoxetine. Patients aged ≥ 18 years with chronic 
non-malignant pain and prescribed buprenorphine, codeine or tramadol between 
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to TMA, the effect sizes were significantly larger in NMA. ConClusions: Network 
meta-analysis of multiple sclerosis trials shows fingolimod as the best treatment. 
Compared to traditional meta-analysis, network meta-analysis enables more robust 
estimation of effect sizes.
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objeCtives: Peripheral neuropathic pain (pNeP) refers to the pain associated with 
the condition of peripheral neuropathy. Postherpetic neuralgia (PHN) is one type of 
pNeP, which is the most common complication of herpes zoster. This study aims to 
determine the effectiveness of pregabalin compared with gabapentin in pNeP and 
PHN in China. Methods: We utilized a 12-week simulation model which tracked 
a cohort of 1,000 patients with pNeP or PHN only, by pain score. A pre-treatment 
distribution of pain scores was collected utilizing a local questionnaire of Chinese 
KOLs for pNeP and PHN. Treatment outcomes for pregabalin (150 – 600 mg) and 
gabapentin (2,400 mg) were taken from the published literature. Results: In the 
PHN scenario, pregabalin was associated with a lower average pain score compared 
with gabapentin (3.92 vs. 4.52). The difference in mean days of no or mild pain, mod-
erate pain, and severe pain were 8.82, -5.74, and -3.06, when comparing pregabalin 
and gabapentin, respectively. Pregabalin had more mean days with a > 30% (7.71 
days), 40% (8.97 days), and 50% reduction (9.97 days) in pain when compared with 
gabapentin. In the pNep scenario, pregabalin was associated with a lower average 
pain score compared with gabapentin (3.91 vs. 4.55). The difference in mean days 
of no or mild pain, moderate pain, and severe pain were 9.39, -5.56, and -3.82, when 
comparing pregabalin and gabapentin, respectively. Pregabalin had more mean days 
with a > 30% (8.77 days), 40% (9.81 days), and 50% reduction (10.55 days) in pain when 
compared with gabapentin. ConClusions: Pregabalin is an effective treatment for 
PHN and even for pNeP extensively. It leads to improved outcomes including lower 
pain scores and more days with no or mild pain.
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objeCtives: We studied the potential for new extended-half-life recombinant fac-
tor IX (rFIX) treatments to reduce the burden of injections and to prevent bleeding. 
We indirectly compared annualized bleed rates (ABRs) and factor consumption 
(FC) during prophylaxis and the FC and number of injections to treat a bleed with 
rFIX Fc fusion protein (rFIXFc) and conventional rFIX products based on estimates 
from published literature. Methods: A systematic review identified studies of 
routine prophylaxis in previously treated adults and adolescents with severe hae-
mophilia B for comparison with rFIXFc (Powell 2013; Arm 1, weekly prophylaxis). 
Comparisons were based on simple differences between studies in median weekly 
FC and mean ABRs during prophylaxis, and the median FC and numbers of injec-
tions per bleed. Median weekly FC during prophylaxis was reported or estimated 
from the reported dose and weekly number of injections; FC per bleed was esti-
mated from the reported dose and number of injections per bleed. The number 
of injections per bleed was calculated from the reported breakdown of bleeds 
by required number of injections or total number of injections divided by total 
bleeds. Results: Three conventional rFIX studies were included: Roth 2001 and 
Lambert 2007 (BeneFIX®) and Windyga 2014 (Rixubis®). During prophylaxis, the 
mean ABR was comparable or lower and FC was lower with rFIXFc compared with 
rFIX (weighted average ABR with rFIX= 4.0 vs. 3.1 with rFIXFc; weighted average 
increase in median weekly FC with rFIX= 108%). The number of injections and FC 
per bleed were also lower with rFIXFc (weighted average number of injections with 
conventional rFIX= 1.5 vs. 1.1 with rFIXFc; weighted average increase in median 
FC per bleed with rFIX= 49%). ConClusions: Indirect comparisons of published 
study results suggest that, compared with conventional rFIX, rFIXFc may require 
reduced FC for prophylaxis and bleed treatment while maintaining similar bleed-
ing rates for patients receiving prophylaxis.
PSY13
Modeling the iMPact of Potential diffeRenceS in Real-WolRd 
adheRence With extended-half-life vS. conventional factoR viii 
and ix on Bleeding
Iorio A1, Krishnan S2, Myrén K3, Lethagen S3, McCormick N4, Karner P4
1McMaster University, Hamilton, ON, Canada, 2Biogen Hemophilia, Cambridge, MA, USA,  
3Sobi, Stockholm, Sweden, 4Analysis Group, Boston, MA, USA
objeCtives: To model the impact of potential differences in adherence to rou-
tine prophylaxis with extended-half-life vs. conventional factor VIII and IX on 
bleeding efficacy for patients with severe haemophilia. Methods: Systematic 
literature reviews identified studies of routine prophylaxis in patients with severe 
haemophilia with conventional recombinant factor VIII (rFVIII) and IX (rFIX) for 
comparison with published studies of two extended-half-life agents (rFVIII and 
rFIX Fc fusion protein, rFVIIIFc and rFIXFc). We developed a model that extrapo-
lates the ABR for a given adherence level as the weighted average of two ABRs from 
clinical trials: those associated with prophylaxis (interpreted in the model as ABR 
associated with 100% adherence) and episodic treatment (interpreted as the ABR 
associated with 0% adherence). We used the model to extrapolate ABRs for con-
ventional products assuming real-world adherence of 76% of clinical trial levels, 
and ABRs for rFVIIIFc and rFIXFc at simulated adherence levels ≥ 76%. Extrapolated 
ABRs were compared using simple differences. We also mapped simulated adher-
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objeCtives: The objective of this literature review was to explore the existing 
evidences regarding the economic evaluation of multidisciplinary pain man-
agement services in managing people with fibromyalgia or chronic widespread 
pain Methods: Electronic search of Embase, MEDLINE, PsychoINFO, NHS EED, 
JBI, and Cochrane database was performed. Studies published from the time of 
the respective database inception to April 2015 were considered for inclusion in 
this review. The quality of studies was assessed using the Cochrane Back Review 
Group and the Consolidated Health Economic Evaluation Reporting Standards 
(CHEERS). Results: The literature review allowed retrieving 620 studies of which 
6 fulfilled the eligibility criteria. All included studies were economic evaluations 
alongside randomized clinical trials published between 1996 and 2015. Two were 
from the UK, two from Spain, and two from the Netherland. Risk of bias was high 
in two studies. The intervention, comparators, disciplines involved, and number of 
sessions were well described in most of the studies. variation between the included 
studies were in type of interventions, length of administration, follow-up period, 
and outcome measured. None of the studies met all CHEERS quality criteria. In 
Five studies, multidisciplinary pain management services were cost-effective at 
short-term follow up; however, this was not always maintained in long term follow-
up. ConClusions: Due to the high level of heterogeneity among selected studies, 
we were unable to make a definitive conclusion about the cost-effectiveness of 
pain management services in managing people with fibromyalgia or chronic wide-
spread pain. Multidisciplinary pain management services trials must be based on 
high methodological and economic quality to determine the cost-effectiveness of 
multidisciplinary pain management services.
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objeCtives: To better understand the impact of new extended-half-life recom-
binant factor VIII (rFVIII) treatments relative to conventional rFVIII, we indirectly 
compared published clinical study results of the factor consumption (FC) and num-
ber of injections to treat a bleed during episodic therapy and the FC and annualized 
bleeding rates (ABR) during prophylaxis with rFVIII Fc fusion protein (rFVIIIFc) and 
conventional rFVIII. Methods: A systematic review identified studies of routine 
prophylaxis in previously treated adults and adolescents with severe haemophilia 
A for comparison with rFVIIIFc (Mahlangu 2014, Arm 1, individualized prophylaxis). 
Comparisons were based on the simple differences between studies in median 
weekly FC, mean prophylaxis ABRs, and the median FC and numbers of injections 
per bleed. Median weekly FC was reported or estimated from the reported dose and 
weekly number of injections; FC per bleed was estimated from the reported dose 
and number of injections per bleed. The number of injections per bleed was calcu-
lated from the reported breakdown of bleeds by required number of injections or 
the total number of injections divided by total bleeds. Results: Four conventional 
rFVIII studies were included: Tarantino 2004 and Valentino 2012 (Advate®), Recht 
2009 (Xyntha®), and Pollmann 2007 (REFACTO®). ABR and weekly FC during proph-
ylaxis were lower with rFVIIIFc compared with each conventional rFVIII study 
(weighted average mean ABR with rFVIII= 5.2 vs. 2.9 with rFVIIIFc; weighted average 
increase in median weekly FC with rFVIII= 24%). The number of injections and FC 
per bleed were comparable or lower with rFVIIIFc vs. each rFVIII study (weighted 
average number of injections with rFVIII= 1.4 vs. 1.2 with rFVIIIFc; weighted aver-
age increase in median FC per bleed with rFVIII= 43%). ConClusions: Based on 
estimates from published literature, rFVIIIFc requires reduced FC for prophylaxis 
and bleed resolution compared with conventional rFVIII while maintaining similar 
or decreased bleeding rates for patients receiving prophylaxis.
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objeCtives: Several new agents have shown positive results in clinical trials for 
prevention of relapses in multiple sclerosis. The objective of this study was to com-
pare network meta-analysis results with traditional meta-analysis. Methods: A 
systematic literature search for randomized clinical trials for multiple sclerosis 
was undertaken for the databases Pubmed, Embase, Biosis, Google Scholar and 
Cochrane. Data was collected for the study type, methods, country and key find-
ings. Extracted study data included study design, patient charatcertristcis and MS 
related outcomes. A bayesian random effects network meta-analysis (NMA) model 
was developed in WinBUGS14. Results were compared to previously published tra-
ditional meta-analysis (TMA). Results: We identified 730 references and found 
10 randomized trials in 4095 patients with 2518 events. The drugs included in our 
study were interferon (IFN), glatiramer (GLAT, natalizumab (NAT) and fingolimod 
(FING). The Odds Ratios (ORs) for FING versus NAT was 1.66 (0.31 – 9.96),FING versus 
GLAT 2.19 (0.50 – 7.49), FING versus IFN 2.25 (0.90 – 5.57), FING versus PLB 4.42 (1.46 
– 14.87), NAT versus GLAT 1.32 (0.22 – 5.40), NAT versus IFN 1.321.35 (0.29 – 5.75), 
NAT versus PLB 2.68 (0.71 – 9.99), GLAT versus IFN 1.03 (0.42 – 3.16), GLAT versus 
PLB 2.04 (0.95 – 5.91), IFN-B versus PLB 1.97 (1.01 – 4.14). The probability to be best in 
preventing relapses was 75.9% for FING, 17.0% for NAT and 6.3% for GLAT. Compared 
